Investigators explored baseline characteristics and predictors of erythropoiesis-stimulating agents (ESA) hyporesponsiveness in a global randomized cardiovascular outcomes study comparing an investigational hypoxia-inducible factor prolyl hydroxylase inhibitor, daprodustat, with conventional (ESA) treatment.
[American Journal of Nephrology]